| Name | Title | Contact Details |
|---|
Stormont Vail Health is a nonprofit integrated health care system that has been serving the health care needs of northeast Kansas for more than 130 years. It is comprised of Stormont Vail Hospital, a 586-bed acute care Magnet®-designated hospital, and Cotton O`Neil Clinic, a multi-specialty physician group with more than 250 physicians. Nearly 5,000 employees provide care and support services for patients in the hospital and 35 other locations, including the Cotton O`Neil Heart Center, Cancer Center, Diabetes & Endocrinology Center, Digestive Health Center, Pediatrics clinics, 10 regional primary care clinics and six Express Care clinics. Stormont Vail Health is committed to its mission of improving the health of the community by being a national leader in providing compassionate, high-quality and efficient integrated care through collaboration that results in a healthier community. Stormont Vail Health is a member of the Mayo Clinic Care Network, a group of more than 40 health care organizations who have joined together to complement their local expertise with the knowledge and experience of Mayo Clinic health care professionals. Stormont Vail`s local partnerships include housing the Bachelor of Science in Nursing program of the Baker University School of Nursing, providing athletic training services to Washburn University Athletics and being a founding partner of the Powercat Health Partnership with Kansas State University and the Kansas Health Foundation.
Hyer Medical is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Parma Care Ctr is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Quantum Health is an award-winning consumer healthcare navigation company that delivers an unparalleled consumer experience based on empathy and trust, enabling employers to achieve industry-leading satisfaction rates and independently validated claim savings. Launched in 1999, Quantum Health’s model is based on years of consumer research and the insights learned from guiding millions of consumers and their providers through their healthcare journey. Based in Columbus, Ohio, Quantum Health has earned numerous awards and honors, including being named a Fastest-Growing Privately Held Company for the past nine years by Inc. 5000; one of the 50 Fastest-Growing Women-Owned/Led Companies for the past four years by the Women Presidents’ Organization; a Best Place to Work for the past 10 years by Columbus Business First; and a Great Place to Work® Best Small & Medium Workplaces by FORTUNE Magazine and Entrepreneur Magazine.